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Background: People with an autistic spectrum disorder (ASD) display a variety of characteristic behavioral traits,
including impaired social interaction, communication difficulties and repetitive behavior. This complex
neurodevelopment disorder is known to be associated with a combination of genetic and environmental factors.
Neurexins and neuroligins play a key role in synaptogenesis and neurexin-neuroligin adhesion is one of several
processes that have been implicated in autism spectrum disorders.
Results: In this report we describe the manual annotation of a selection of gene products known to be associated
with autism and/or the neurexin-neuroligin-SHANK complex and demonstrate how a focused annotation approach
leads to the creation of more descriptive Gene Ontology (GO) terms, as well as an increase in both the number of
gene product annotations and their granularity, thus improving the data available in the GO database.
Conclusions: The manual annotations we describe will impact on the functional analysis of a variety of future
autism-relevant datasets. Comprehensive gene annotation is an essential aspect of genomic and proteomic
studies, as the quality of gene annotations incorporated into statistical analysis tools affects the effective
interpretation of data obtained through genome wide association studies, next generation sequencing,
proteomic and transcriptomic datasets.
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The Gene Ontology (GO; www.geneontology.org) con-
tains controlled vocabulary terms (GO terms), which are
connected through defined relationships within a hier-
archical order (Fig. 1) [1]. The association of GO terms
with gene products enables proteins to be classified
(grouped) according to their shared normal molecular
functions, the biological processes they contribute to, and
their location with respect to subcellular compartments
(cellular components). Summarising the known role of
gene products from published papers to populate the
GO database, a process known as annotation, allows re-
searchers to have access to information on the role of* Correspondence: r.lovering@ucl.ac.uk
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creativecommons.org/publicdomain/zero/1.0/individual proteins and protein families in the form of
controlled vocabulary terms [2]. GO provides one of the
major annotation resources used for the analysis of
high-throughput datasets, such as those from transcrip-
tomic and proteomic studies, to identify pathways, func-
tions or cellular components over-represented within a
dataset. For example, common GO domains found in an
analysis of a brain transcriptomic dataset associated with
aging in the prefrontal cortical regions were calcium sig-
nalling, protein tyrosine kinase signalling, electrical ex-
citability and neuropeptide hormones [3]. In addition,
GO is also being used in pathway-driven analysis tools
to identify risk Single Nucleotide Polymorphisms (SNPs)
associated with specific phenotypes, and to inform bio-
marker identification studies [4–6]. However, the inter-
pretation of these datasets depends on the quality of the
gene annotations available and the statistical analysis
tools used, and we have previously demonstrated thatcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Part of the synapse domain of the GO cellular component ontology. The QuickGO (http://www.ebi.ac.uk/QuickGO) view of the parent–child
relationships between the GO terms ‘postsynaptic membrane’ and ‘cellular component’. The black arrows are used where a term has an ‘is_a’
relationship to its parent term, the blue arrows indicate a ‘part_of’ relationship, www.geneontology.org/GO.ontology.relations.shtml
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cantly improves the interpretation of cardiovascular-
relevant datasets [7].
Autistic spectrum disorder (ASD) is a complex neurode-
velopmental condition known to be associated with a
combination of genetic [8] and environmental factors [9].
ASD is often diagnosed around 3 years of age and many ofthe characteristic traits continue to adulthood [10]. Pa-
tients with ASD (as classified by the Diagnostic and Statis-
tical Manual of Mental Disorders, Fifth Edition, DSM-5)
[11] exhibit a variety of behavioral deficits, such as social
interaction and communication difficulties and restrictive
and repetitive behavior [12]. Limited social interaction by
ASD children is often interpreted as a lack of social
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ASD children to engage with others [13–15]. ASD patients
also have limited communication skills, such as gesture,
facial expression and speech deficits. Repetitive stereotype
behaviors are usually detailed and structure orientated,
where the activity and/or behavior contains a number of
steps in order to complete the task [13, 14].
There is strong evidence for multiple genetic factors
determining the development of ASD. To date, around
40 genomic loci and over 100 genes have been associ-
ated with ASD based on rare variant approaches. These
approaches have identified sequence and copy number
variants as well as chromosomal rearrangements [16].
These genes and loci have been identified based on
SNPs, de novo losses or gain mutations and linkage stud-
ies [17, 18]. Although many single genes have been im-
plicated, a complete understanding of ASD is still to be
achieved. A key obstacle for researchers is that these
SNPs or mutations are not common in all patients with
ASD, consequently the identification of low frequency
SNPs associated with ASD is challenging.
Synaptogenesis, chromatin re-modeling, morphogenic
developmental processes, calcium homeostasis and mito-
chondrial function have all been identified as potentially
contributing to ASD [18]. In this study, we have focused
on the manual annotation of the neurexin, neuroligin and
SHANK protein families, as the interaction between the
neurexin and neuroligin cell adhesion molecules is one of
the processes that has been implicated in the development
of ASD [18]. However, variants in the neurexin, neuroligin
and SHANK gene families have only been associated with
a few percent of ASD cases [18].
Neurexins (NRXNs) and neuroligins (NLGNs) are
single-pass transmembrane proteins that play a key role
in synaptogenesis, a process which occurs before birth
and continues into adulthood [19]. In the process of syn-
apse formation, the NLGN and NRXN cell surface adhe-
sion molecules interact in a calcium-dependent manner
to initiate the first stage of synapse formation and the
assembly of protein components required for presynap-
tic and postsynaptic cell membrane organization [20,
21]. The intercellular interaction between NRXNs and
NLGNs facilitates axo-dendritic contact [19, 21], and the
synapse that is formed becomes stabilized or eliminated
based on the synaptic activity, which is driven by the ac-
tion potential between two or more neurons [22]. The
scaffolding SHANK proteins are required for the proper
formation and function of neuronal synapses and are
connected to NLGN cell adhesion molecules via their
interaction with DLG4 (PSD-95, postsynaptic density-
95) to facilitate postsynaptic organization of cytoskeletal
and signaling complexes [23].
ASD-associated variants have been identified in mem-
bers of both the NLGN [24] and NRXN [25, 26] genefamilies. Although all five members of the NLGN gene
family are associated directly with synapse assembly
[27–29], mutations in only 3 members of this family,
NLGN3, NLGN4X and NLGN4Y, have been identified in
autistic patients [24, 30–32]. There are also five mem-
bers of the NRXN gene family in humans: NRXN1,
NRXN2, NRXN3 [33] and two NRXN4 genes known as
CNTNAP1 and CNTNAP2 (Contactin-associated protein 1
and 2 respectively) [34]. NRXN1-3 encode alpha and beta
isoforms which have identical C-terminal transmembrane
regions and cytoplasmic tails. However, alternative pro-
moter use leads to the isoforms having different N-
terminal extracellular sequences, the α-isoforms having
much longer extracellular domains than the β-isoforms
[29]. UniProt recognises these differences by providing
unique identifiers for each isoform, rather than treating
the isoforms as splice variants and listing the variants
within a single protein record. Both the α- and β-
isoforms have been associated with synapse forma-
tion [35], whereas the proteins encoded by CNTNAP1 and
CNTNAP2 are involved in non-synaptic neurogenic pro-
cesses [36, 37]. Mutations associated with ASD are found
in both alpha and beta NRXN1 [26, 38], NRXN2 [39],
NRXN3 [40] and CNTNAP2 [41]. Furthermore, variants in
all three SHANK family members have been associated
with ASD [42–44]. Neuroligin, neurexin and SHANK mu-
tations link ASD with the molecular components of syn-
aptogenesis. Therefore investigating the functional role of
the proteins associated with the neurexin-neuroligin-
SHANK complex in model organisms may explain how
the mutations in some of these proteins result in the be-
havioral traits seen in some patients with ASD. DLG4 was
also included in this focused annotation project due to its
role as a scaffold protein connecting the NLGN and
SHANK proteins [45].
Comprehensive manual annotation of the NRXN,
NLGN, SHANK and DLG4 proteins identified several
GO domains that are associated with the majority of
these proteins, including behavior, synaptogenesis and
neurogenesis. During the annotation process we identi-
fied a lack of GO terms which could describe the role of
NRXNs and NLGNs in the process of synaptogenesis; to
fill this void, new synapse assembly GO terms were cre-
ated. These new GO terms were then associated with
the NRXN, NLGN, SHANK and DLG4 proteins, when
there was supporting experimental evidence. Further-
more, confirmed orthology predictions between the
human, rat and mouse ASD-associated proteins sup-
ported the propagation of GO annotations from each pro-
tein to the orthologous proteins in these species (http://
www.geneontology.org/cgi-bin/references.cgi#GO_REF:00
00024) [2]. These new GO annotations and terms are now
included in the GO database, enriching both the annota-
tion data and the ontology structure.
Patel et al. BMC Bioinformatics  (2015) 16:186 Page 4 of 17Methods
Selection of experimental data to annotate
The PubMed database (http://www.ncbi.nlm.nih.gov/
pubmed) was used to locate papers that contained ex-
perimental data describing each member of the NRXN,
NLGN, SHANK or DLG4 protein families. The searches
were performed, during April to November 2011, using
the following gene names and symbols: neurexin, neuro-
ligin, NRXN*, NLGN*, SHANK1, SHANK2, SHANK3,
CASPR, DLG4, DLG-4, PSD95, PSD-95. This search re-
trieved over 2000 papers. Consequently, we undertook a
PubMed search with each individual gene symbol or
name and additional filters, in order to provide a com-
prehensive coverage of the role of these proteins with re-
spect to autism. The following filters were applied to
each of the symbol and name searches: ‘AND autism/
ASD’ , ‘AND synaptogenesis/synapse assembly’ , ‘AND aut-
ism/ASD AND synaptogenesis/synapse assembly’. The
number of papers available that described each gene influ-
enced the number of filters applied. The decision about
which paper to annotate was then based on whether: 1)
new information would be added to the current GO anno-
tation data associated with the protein; 2) it was possible
to identify the species the protein or transfected cDNA
construct was derived from. Only papers that met both
criteria were annotated. The choice of papers annotated
was therefore influenced by the information captured in
previously annotated papers. In total, 66 papers with ex-
perimental data that were relevant to ASD or synapto-
genesis were originally selected for annotation. However,
following the identification of an association of NLGN4Y,
NRXN2 and NRXN3 alpha and beta variants with ASD
[39, 40], these two additional papers were also annotated
(February 2014) bringing the total number of papers anno-
tated to 68 (see Additional file 1).
Identification of orthologous proteins
Orthologous proteins were identified for the NRXN,
NLGN, SHANK and DLG4 protein families between
the human, mouse and rat species, using the HUGO
Gene Nomenclature Committee (http://www.genename-
s.org/) ortholog prediction tool (HCOP). HCOP compiles
data from 11 different orthology prediction tools, including
EnsemblCompara, Homologene and Inparanoid [46]. The
predicted ortholog amino acid sequences were also aligned,
using the default settings on the Basic Local Alignment
Search Tool – BLASTP (http://blast.ncbi.nlm.nih.gov/
Blast.cgi), to confirm high homology. In all cases there was
greater than 89 % amino acid sequence identity between
these aligned mammalian orthologs.
Gene Ontology annotation - manual curation process
Manual GO annotation requires a GO curator to read
publications and convert the data presented into anannotation. Each annotation includes the protein identi-
fier, a GO term, an evidence code, and a reference [2].
During this focused annotation project GO terms were as-
sociated with protein records based on experimental data
describing the human, rat and mouse NRXN, NLGN,
SHANK and DLG4 proteins. The QuickGO browser
(http://www.ebi.ac.uk/QuickGO) was used to identify the
most specific GO terms to ‘capture’ the experimental data
presented in each paper, and a consistent annotation ap-
proach was undertaken [2]. Evidence codes were associ-
ated to each annotation based on the type of experimental
data presented in the paper (www.geneontology.org/GO.
evidence.shtml) [2]. To complete the manual annotation
process, GO annotations with experimental evidence
codes were transferred to orthologous human, mouse and
rat proteins. These annotations include the ISS (Inferred
from Sequence Similarity) evidence code. New, more de-
scriptive GO terms were created, along with improve-
ments to the ontology structure, using the GO editorial
tool, OBO-Edit [47].
Results and discussion
GO annotation of the neurexin, neuroligin, SHANK and
DLG4 protein families
There are several thousand publications describing the
mammalian members of the NRXN, NLGN, SHANK
and DLG4 protein families. With limited resources avail-
able, we restricted our manual annotation focus to ex-
perimental data describing the functional role and
cellular location of these proteins, where there was a
clear relevance to synaptogenesis and autism. Conse-
quently, only a fraction of the available experimental
data describing the NRXN, NLGN, SHANK and DLG4
proteins has been captured. Synaptogenesis and other
pathways that impact on behavior are complex pro-
cesses, involving numerous proteins, and full annotation
of these processes is not attempted in this report. GO
terms were associated with the mammalian members of
the NRXN, NLGN, SHANK and DLG4 protein families
based on the experimental data present in 68 published
experimental papers (see Additional files 1, 2 and 3), in-
creasing the number of papers contributing to the man-
ual annotations of these proteins from 172 to 240.
Whenever possible, annotations were created that cap-
ture the molecular function of each protein, the bio-
logical processes these proteins contribute to, and their
intracellular location (cellular component, see Additional
file 4). This approach has created over 500 publication-
supported manual annotations (see Additional files 3, 4,
5 and 6), doubling the previous number of these annota-
tions to over 1000. In addition, to maximise the utility of
this annotation project, almost 700 GO annotations were
propagated to orthologs in the three species annotated
(human, mouse and rat). These annotations are identified
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ity) evidence code and were only created when orthol-
ogy was confirmed and when the GO term was not
already ‘manually’ associated with the protein record
[2]. The propagation of annotations across these mam-
malian orthologs increased the number of manual an-
notations to these 47 proteins to over 1800 (see
Additional file 3). There are now molecular function,
biological process and cellular component annotations
associated with almost all members of these families
supported by confirmed experimental data. No experi-
mental data was identified to support cellular compo-
nent annotations for the human, mouse or rat NLGN4Y,
NRXN2 and NRXN3 proteins, or to support molecular
function annotations for the mouse or rat Nlgn4l pro-
teins. This annotation approach has meant that over
400 unique GO manual annotations, directly supported
by experimental evidence, are now associated with the
human NRXN, NLGN, SHANK and DLG4 protein fam-
ilies. The BHF-UCL and UniProt-GOA teams have cre-
ated the majority of manual annotations associated with
the human NRXNs, NLGNs, SHANKs and DLG4 pro-
tein families (see Additional file 7).
The full definition and ontology placement for each
GO term listed below is available in the QuickGO term
page using the hyperlinks provided.
Cellular component GO terms
The manual annotation of 87 papers confirms the cellular
location of many of the human, rat and mouse NRXN,
NLGN, SHANK and DLG4 proteins (see Additional files 3
and 4). These cellular component GO annotations are pri-
marily associated with either the evidence code IDA
(Inferred from Direct Assay) or ISS. Furthermore, many of
these cellular component manual annotations describe the
neuron-relevant localisation of these proteins, such as ‘ex-
citatory synapse’, ‘postsynaptic membrane’, and ‘dendrite’
(Fig. 2).
NRXNs and NLGNs contain a single transmembrane
region, and their involvement in cell adhesion suggests
they are located in the plasma membrane. Experimental
evidence supports the association of the GO terms
‘plasma membrane’ and ‘cell surface’ with many of these
proteins. However, in order to associate the GO term
‘plasma membrane’ with human NRXN1-α the evidence
code IC (Inferred by Curator) is applied. This inference is
based on the immunofluorescence analysis of NRXN1-α
transfected COS cells [39], which supports the NRXN1-α
‘cell surface’ annotation, along with the knowledge that this
protein contains a transmembrane domain and is there-
fore likely to be located in the plasma membrane.
The NRXN, NLGN, SHANK and DLG4 proteins play
a key role in synapse assembly and there is considerable
experimental evidence to support GO annotationsdescribing the localization of these proteins to neuronal-
specific components, such as ‘excitatory synapse’ [23,
48–52] and ‘dendrite’ [28, 51, 53, 54]. In addition, while
the majority of the NRXN family are associated with the
synapse, the CNTNAP proteins are located in the ‘juxta-
paranode region of axon’ and ‘paranode region of axon’
[36, 37] (Fig. 2, see Additional files 3 and 4).
Biological process GO terms
Several neurological processes are associated with the
NRXN, NLGN, SHANK and DLG4 proteins families,
such as neurogenesis, synaptic organisation, synaptic
transmission, and behavior (Fig. 3). In contrast,
CNTNAP1 and CNTNAP2 are involved in axon assem-
bly, with CNTNAP1 required for neuronal action poten-
tial propagation [37, 55]. The cellular component and
biological process annotations associated with the
CNTNAPs reflect the lack of evidence for a role of these
proteins in synaptic processes and identifies these pro-
teins as functionally distinct from the other members of
the NRXN family.
Synapse assembly
A synapse includes cellular components contributed by
two adjacent cells. Consequently, synapse assembly
covers a wide variety of processes, including presynaptic
membrane assembly, postsynaptic membrane assembly,
postsynaptic density assembly and the clustering of the
various adhesion molecules, receptors, channels and
scaffold proteins.
The calcium-dependent interaction between an NLGN
and NRXN protein, located in different cells, initiates
the first stage of synapse formation [20, 21, 49, 56].
Therefore, NRXNs and NLGNs are annotated with ‘cal-
cium-dependent cell-cell adhesion via plasma membrane
cell adhesion molecules’ [35], ‘heterophilic cell-cell adhe-
sion via plasma membrane cell adhesion molecule’
[35, 57]’ and ‘neuron cell-cell adhesion’ [29, 35, 56]. In
addition, the NRXNs and NLGNs play an essential role
in the clustering of proteins at the presynaptic mem-
brane and postsynaptic membrane during synapse as-
sembly [21, 35, 48]. In order to capture the specific
detail of synapse assembly new, highly descriptive GO
terms have been created (Table 1, Fig. 4). The assembly
process involves organization of the synaptic membrane
on either side of the synapse [35], consequently two new
GO terms were created, ‘postsynaptic membrane assem-
bly’ and ‘presynaptic membrane assembly’ with ‘is_a’
child relationships to the biological process GO terms
‘postsynaptic membrane organization’ or ‘presynaptic
membrane organization’, respectively. These new GO
terms enabled the mouse Nrxn1-α, Nrxn1-β, Nrxn2-α
and Nlgn1-3 [35, 39, 48, 58] to be annotated with ‘post-
synaptic membrane assembly’ based on experimental
Fig. 2 Cellular component GO terms associated manually to the ASD-relevant human proteins. A subsection of the cellular component domain,
with the human protein families (blue ovals) and their associated GO terms (white boxes), linked with red dotted line (see Additional file 4). All
associations (except ‘Inferred from Electronic Annotation’ (IEA) supported data) are included. If one or several member(s) of a protein family is
associated with a specific term then the family name, or the protein name DLG4, is listed below the term. ‘ALL’ is used when a member of the
CNTNAP, NLGN, NRXN, SHANK families as well as DLG4 have been associated with the GO term. The numbered circle indicates the minimum
number of GO terms in the ancestor chart between two of the listed GO terms. For example there are 2 GO terms (‘synaptic membrane’ and
‘synapse part’) between the GO terms ‘synapse’ and ‘postsynaptic membrane’ (Fig. 1)
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Nlgn2 ectopic expression, in mixed culture assays, sup-
ports the association of ‘presynaptic membrane assembly’
[21, 35, 48]. Furthermore, to capture the involvement of
NLGNs and NRXNs in initiating the clustering of specific
proteins and organelles to synaptic locations, additional
new GO terms have been created (Table 1, Fig. 4). Cluster-
ing of scaffold and receptor proteins is part of the process
of postsynaptic and presynaptic membrane organization.
Therefore, new GO terms, describing the clustering of
these specific proteins, were created as ‘part_of ’ child
terms to either ‘postsynaptic membrane organization’ or
‘presynaptic membrane organization’ terms, with ‘is_a’
child relationships to ‘protein localization to membrane’, or
part_of child terms to ‘postsynaptic density assembly’, with
‘is_a’ child relationships to ‘protein localization to synapse’.
There is considerable experimental evidence describing the
clustering of specific proteins at the synaptic membrane
area. For example Gauthier et al., [39] showed that when
Nrxn2-α is mutated there is impairment in GABAergic
postsynaptic components and gephyrin at the dendrite
contact sites of postsynaptic neurons [48]. Experimental
data such as this has been used to support the association
of the new GO term ‘gephyrin clustering involved inpostsynaptic density assembly’ with Nrxn1-α, Nrxn1-β and
Nrxn2-α and the new GO term ‘postsynaptic density pro-
tein 95 clustering’ with Nrxn1-α, Nrxn1-β, Nrxn2-α, Ngln1
and Nlgn2 [35, 39, 48, 59] (Fig. 4).
Following common practice when creating GO terms,
the cellular component ontology was used to guide the
biological process ontology. For example, the cellular
component term ‘postsynaptic density’ ‘is_a’ child term of
‘cytoskeletal part’ and, therefore, in the biological process
ontology ‘postsynaptic density organization’ has an ‘is_a’
relationship link with ‘cytoskeleton organization’. Bio-
chemical analysis of postsynaptic densities purified from
the striatum of wild type and Shank3B−/− mice demon-
strates that the Shank3 protein is required for correct
postsynaptic density assembly [23]. Consequently, the
new GO term ‘postsynaptic density organization’ is asso-
ciated with murine Shank3.
Synaptic vesicle clustering occurs at the presynaptic
membrane, as well as below this membrane. Therefore,
the new GO term ‘synaptic vesicle clustering’ is placed as
part_of ‘presynaptic active zone assembly’ rather than as a
child term of ‘presynaptic membrane organization’. This
‘synaptic vesicle clustering’ GO term is associated with
both murine Nlgn1 and Nrxn1-β, based on Nlgn1 ectopic
Fig. 3 Distribution of biological process GO terms associated to each of the selected human protein records. The GO terms ‘directly’ associated
with a human protein record have been grouped into broader biological process parent GO term categories (see Additional file 5). Due to the
structure of the ontology there are some GO terms that are child terms of more than one of these broader GO parent terms. In these instances
the annotation is then represented more than once in the histogram. No IEA annotations are included in the histogram
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markers in cultured hippocampal neurons, following
oligomerization of overexpressed murine Nrxn1-β,
respectively [21, 35, 60].
The two closely related paralogs CNTNAP1 and
CNTNAP2 are both associated with neurogenesis, but
only CNTNAP2 has been found to be associated with
ASD [61]. In contrast to the other members of the
NRXN family, CNTNAP1 is found on paranode region
of axons [36, 37], whereas CNTNAP2 is located on the
juxtaparanode region of axons [36, 62]. Furthermore,
CNTNAPs appear to play a role in axon assembly, rather
than synapse assembly. For example, Garcia-Fresco et al.
[37], show impaired localization of mitochondria and
neurofilament to the paranodal region of the axon in
mice deficient in Cntnap1. Based on this experimentalevidence the GO term ‘protein localization to paranode
region of axon’ is associated with murine Cntnap1 pro-
tein record (see Additional file 5) [55]. Furthermore, de-
letion of Cntnap2 in mice demonstrates that Cntnap2 is
required for clustering of voltage-gated potassium chan-
nels to the juxtaparanodal region of myelinated axons,
similar to the role of NRXNs in neurotransmitter-gated
ion channel clustering at the synapse [63]. This data was
captured using the GO terms: ‘clustering of voltage-gated
potassium channels’ and ‘protein localization to juxta-
paranode region of axon’.
The synaptic scaffold SHANK family members and
DLG4 are also key proteins in synapse assembly, providing
essential structural support, and are involved in bringing
necessary protein components to the synapse [48, 52].
Wang et al. [64] identifies that levels of Homer1b/c and
Table 1 New GO terms created to support detailed ASD-relevant annotations. The ancestral relationship of these new GO terms is
described in Figs. 4 and 5 (with the exception of the new protein binding terms and ‘receptor localization to synapse’). The term
records in the QuickGO browser (http://www.ebi.ac.uk/QuickGO) provide the full definition and ontology placement for each GO
term provide the full definition and ontology placement for each GO term. The reference column lists the references used as a
source of information when creating each term
New GO Term GO ID Reference
Synapse assembly terms
Postsynaptic density assembly GO:0097107 [65]
Postsynaptic density organization GO:0097106 [65]
Postsynaptic membrane assembly GO:0097104 [39]
Presynaptic membrane assembly GO:0097105 [56, 68]
Presynaptic membrane organization GO:0097090 [49]
Regulation of postsynaptic membrane potential terms
Negative regulation of excitatory postsynaptic membrane potential GO:0090394 [49]
Positive regulation of excitatory postsynaptic membrane potential GO:2000463 [77]
Positive regulation of inhibitory postsynaptic membrane potential GO:0097151 [68]
Protein clustering/localization terms
Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor clustering GO:0097113 [35]
Gamma-aminobutyric acid receptor clustering GO:0097112 [48]
Gephyrin clustering involved in postsynaptic density assembly GO:0097116 [48]
Guanylate kinase-associated protein clustering GO:0097117 [48]
Neurexin clustering involved in presynaptic membrane assembly GO:0097115 [35]
Neuroligin clustering involved in postsynaptic membrane assembly GO:0097118 [35]
N-methyl-D-aspartate receptor clustering GO:0097114 [48]
Postsynaptic density protein 95 clustering GO:0097119 [80]
Receptor localization to synapse GO:0097120 [65]
Protein binding terms
Neuroligin family protein binding GO:0097109 [39]
Scaffold protein binding GO:0097110 [80]
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in the synaptic plasma membrane are lower in Shank3e4–9
mice, compared to wild type mice. GluA1 is a subunit of
the AMPA receptor; therefore, the GO term ‘alpha-
amino-3-hydroxy-5-methyl-4-isoxazole propionate selective
receptor clustering’ is associated with the mouse Shank3
protein record. This term is also applied to the rat Dlg4
protein, as RNA interference knockdown of rat Dlg4 in
mixed culture assay leads to a reduction in the number of
AMPA receptor type structures near the synapse com-
pared to controls [65]. Further experimental evidence also
supports the role of other NLGN, NRXN, SHANK and
DLG4 proteins in the process of AMPA, GABA and
NMDA receptor clustering in glutamatergic postsynaptic
cells, and GO annotations capturing this information are
now available [35, 48, 59, 64–67] (Fig. 4, see Additional
files 5 and 8).
Regulation of postsynaptic membrane potential
Experimental evidence supports the association of the GO
term ‘regulation of excitatory postsynaptic membranepotential’ (or child terms) with the NLGN, NRXN,
SHANK and DLG4 proteins [28, 51] (Fig. 5, see Additional
files 5 and 8). For example, cultured neurons transfected
with rat Nlgn1(R473C), corresponding to a human variant
associated with an autism disorder, showed a decrease in
excitatory synaptic transmission for both AMPA receptor
and NMDA receptor response, suggesting positive regula-
tion of this process [51]. In contrast, neurons transfected
with human NLGN4X selectively suppress the frequency
of mEPSCs but not mIPSCs, suggesting that NLGN4X is
involved in ‘negative regulation of excitatory postsynaptic
membrane potential’ [28]. Transfection and transgenic
data also supports the association of ‘regulation of inhibi-
tory postsynaptic membrane potential’ (or child terms)
with mouse and rat Nlgn2 and Nlgn3 proteins [48, 51, 68,
69] (Fig. 5, see Additional files 5 and 8). Neurons trans-
fected with rat Nlgn3(R471C), corresponding to another
ASD associated variant, have a decreased inhibitory post-
synaptic membrane potential [69]. Although both Nlgn2
and Nlgn3 [50] are found within inhibitory and excitatory
synapses, the expression of Nlgn2 and Nlgn3 is greater at
Fig. 4 Ancestral relationships of the new GO terms created to support detailed ASD-relevant annotations in the domain of synapse organization.
A subsection of the ‘synapse organization’ domain ontology, human protein families (blue ovals) and their associated GO terms (green boxes),
linked with red dotted line (see Additional files 5 and 8); all associations (except IEA-supported data) are included. If one or several member(s) of
a protein family is associated with a specific term then the family name, or the protein name DLG4, is listed below the term. * indicates new GO
terms (Table 1). Black arrows indicate an ‘is_a’ relationship between a term and its parent; blue arrows indicate a ‘part_of’ relationship
Patel et al. BMC Bioinformatics  (2015) 16:186 Page 9 of 17the inhibitory synapse [48, 51, 69]. This difference of ex-
pression appears to be reflected in their role in the regula-
tion of membrane potentials. The role of the NRXN and
NLGN proteins in excitatory and inhibitory synaptic
transmission suggests that a balance between these pro-
cesses is necessary for normal brain development and that
the dysregulation of these processes may be linked to the
behavioral phenotypes seen in ASD individuals [19]. How-
ever, NRXN, NLGN, SHANK and DLG4 proteins also play
a role in synaptic plasticity [70], which is also likely to con-
tribute to the ASD phenotypes.
Social behavior
Impaired communication and social behavior are the key
behavioral changes seen in ASD individuals, and variants
in the NRXN [26, 38], NLGN [28, 71], SHANK [42–44]
gene families as well as in the CNTNAP2 gene are associ-
ated with ASD [72]. Consequently, using patientinformation provided by papers describing the association
of variants in these genes with ASD, it was possible to
apply several behavioral GO terms to these protein re-
cords, including ‘social behavior’ , ‘vocal learning’ and
‘adult behavior’ (Table 2, see Additional files 5 and 8).
Model organisms have been used to investigate the im-
pact of ASD-associated gene mutations on animal behav-
ior. Simple behaviors in model organisms can provide
information about the more complex behaviors seen in
humans. For example, Hines et al. [68], measured social
behavior in rats by recording how often a rat would
choose to visit a room with another rat in it, compared to
visiting a room without another rat in it. While a wild type
rat would visit the occupied room more often than the
empty room, a rat carrying an Nlgn2 mutation displayed
no preference between either rooms [68]. These types of
rat and mouse behavioral studies were annotated, using
the GO term ‘social behavior’. This simple behavior is
Fig. 5 Ancestral relationships of the new GO terms created to support detailed ASD-relevant annotations in the domain of cell communication. A
subsection of the ‘cell communication’ domain ontology, human protein families (blue ovals) and their associated GO terms (green boxes), linked with
red dotted line (see Additional files 5 and 8); all associations (except IEA-supported data) are included. If one or several member(s) of a protein family is
associated with a specific term then the family name, or the protein name DLG4, is listed below the term. * indicates new GO terms (Table 1). Black
arrows indicate an ‘is_a’ relationship between a term and its parent; blue arrows, a ‘part_of’ relationship; yellow arrows, a ‘regulation’ relationship; green
arrows, a ‘positive_regulation’ relationship
Patel et al. BMC Bioinformatics  (2015) 16:186 Page 10 of 17similar to that observed in ASD individuals, where there is
no eye contact or interest in another person in the room,
and this ASD phenotype is also captured using the GO
term ‘social behavior’ [24, 39, 44, 72].
Vocalization is also impaired in mice and rats carrying
defects in Shank [73], Nlgn4l [74] or Dlg4 [75] genes.
For example, male Shank3 heterozygous mice make
fewer ultrasonic vocalizations to female mice, compared
to their male wild type littermates [70]. This experimentsupports the annotation ‘vocalization behavior’. Simi-
larly, there is often an impairment of communication in
ASD individuals with variants in the NRXN1-α [38],
NRXN1-β [26], CNTNAP2 [41], NLGN4X [24, 28] and
SHANK1 [76] genes (Table 2). These ASD communica-
tion traits are captured either with the use of ‘vocalization
behavior’ or more specifically ‘vocal learning’. Human pro-
teins are only associated with the GO term ‘vocal learning’
when the authors provide detailed information about a
Table 2 Biological process behavioral GO terms associated with the ASD-relevant human and mouse proteins
Human Mouse
GO term name NLGN3 NLGN4X NLGN4Y NRXN1-α NRXN1-β NRXN2-α NRXN3-α NRXN3-β CNTNAP2 SHANK1 SHANK2 SHANK3 Nlgn2 Nlgn3 Nlgn4l Nrxn1-α Dlg4 Shank1 Shank2 Shank3
adult behavior X X X X X X X X X X X X X
learning X X X X X X X X X X X X X
social behavior X X X X X X X X X X X X X X X X X X
vocalization
behavior
X X X X X X X X X X X X X X X X X
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(see Additional files 3 and 5).
Behavior phenotypes described in mouse or rat cannot
be mapped exactly to human behaviors. Furthermore,
some of these behavioral traits are not relevant to hu-
man, such as ‘male courtship behavior’ and ‘olfactory be-
havior’. Consequently, very few behavioral annotations
have been transferred from mouse or rat proteins to the
human orthologs (Table 2, see Additional files 5 and 8).
For example, behavioral studies support the association
of the GO term ‘regulation of grooming behavior’ with
the mouse Shank3, Dlg4 and Nrxn1-α proteins [23, 75,
77]. These annotations have been transferred, using the
ISS evidence code, to the rat orthologs but not to the
orthologous human proteins. Similarly the GO term ‘ex-
ploration behavior’ and its child term ‘locomotory explor-
ation behavior’ are associated with the mouse Shank2 [54]
and Shank3, Dlg4 and Nlgn2 [23, 75, 78] proteins (respect-
ively), but not propagated to the human orthologs. In
addition, we found no published evidence that variants in
DLG4 and NLGN2 are associated with behavioral traits in
human (Table 2, see Additional files 5 and 8).
Molecular function GO terms
The majority of molecular function GO terms associated
with the members of the NRXN, NLGN, SHANK and
DLG4 gene families capture information about the pro-
tein interactions they participate in (Table 3, see
Additional file 6). To provide full annotation of the func-
tion of these proteins two new GO terms were created:
‘neuroligin family protein binding’ and ‘scaffold protein
binding’ (Table 1). These new terms enable the interac-
tions between the NRXN, NLGN, SHANK and DLG4
proteins to be described with the use of the GO terms
‘neurexin family protein binding’ [28, 35, 39, 71], ‘neuroli
gin family protein binding’ [39, 79] and ‘scaffold protein
binding’ [79–81] (Table 3, see Additional file 6). The mo-
lecular function annotations were also used to identify
the specific classes of receptors bound by the SHANK
and DLG4 proteins, such as ‘ionotropic glutamate receptor
binding’ [53], ‘beta-1 adrenergic receptor binding’ [82] and
‘P2Y1 nucleotide receptor binding’ [83]. In addition, the
NRXN and NLGN proteins are associated with ‘receptor
activity’ [35, 39, 56, 68], whereas the SHANK proteins are
associated with the GO term ‘GKAP/Homer scaffold activ-
ity’ [48, 52, 80] (Table 3, see Additional file 6).
Impact of focused annotation approaches on data
interpretation
Members of the GO Consortium have undertaken a var-
iety of focused manual annotation approaches to anno-
tate the human proteome. Two large manual annotation
efforts include renal and cardiovascular focuses [7, 84],
while other projects have focused on specific cellularcomponents, e.g. the peroxisome [85], or specific indi-
vidual genes, e.g. those annotated by the Reference Gen-
ome Project [86]. It is possible that these focused
annotation approaches could lead to a bias in the human
annotation data, which could impact on the analysis of
high-throughput datasets. However, to date, there is no
evidence of unexpected cardiovascular, renal, peroxisome
or neurological terms being detected in term enrichment
analyses [7, 84]. Furthermore, during the manual annota-
tion of these 4 protein families, 68 additional genes were
annotated based on the evidence presented in these 68 pa-
pers, reducing any potential arising bias.
Since their creation, the 19 new GO terms have been
associated with 58 distinct human proteins creating 158
annotations (see Additional file 9); of these, only 31 an-
notations are based on experimental data, the majority
of the remainder have been created through the transfer
of annotations dependent on orthology assertions. Fifty-
two of these annotations capture protein binding inter-
actions whereas the remaining 106 are associated with
the new synaptogenesis related terms. In addition to the
NRXN, NLGN, SHANK and DLG4 proteins, 27 other
proteins, APOE, ATP2B4, CELF4, CEP112, CHRNA7,
DRD4, GRID2, GRIN1, HOMER1, IKBKB, IL1RAPL1,
LRP4, MAP3K7, MDM2, MTMR2, NLGN4X, NOS1,
NPY2R, P2RX7, P2RY1, PANX1, PRKCZ, PTEN,
PTK2B, PTPRD, RELN, S1PR2, SCN5A, are annotated
to these new biological process GO terms. All of the new
GO terms presented in this paper, apart from scaffold pro-
tein binding, are directly relevant to synaptogenesis in the
context of ASD, demonstrating the impairment in the
NGLN-NRXN-SHANK complex. Future annotation of
proteins involved in synaptogenesis may provide a useful
approach to explore and identify other ASD risk candi-
dates. All of the new GO terms presented here were cre-
ated in August 2011 or earlier, and yet the majority of 104
manual annotations to human proteins applying these GO
terms (in March 2014) were created during this focused
annotation project (91 annotations). For highly specific
annotations to be created by manual GO curation the cu-
rators need to feel confident in the biological field they are
annotating. Curators working within a specific annotation
project improve their understanding of a biological area
and improve their knowledge of the GO terms available to
describe the experiments they are annotating. The high
number of annotations using these new GO terms created
by this focused project, compared to the number created
by other groups, highlights the importance of focused an-
notation approaches to comprehensive annotation of the
human genome. However, annotation projects that target
the annotation of large number of proteins, such as the
UniProt-GO annotation project [87], ensure the breadth
of annotation is maintained and reduce the bias within the
GO database.
Table 3 Selection of the molecular function GO terms associated with the ASD-relevant human proteins
GO term name NLGN1 NLGN2 NLGN3 NLGN4X NLGN4Y NRXN1-α NRXN1-β NRXN2-α NRXN2-β NRXN3-α NRXN3-β CNTNAP1 SHANK1 SHANK2 SHANK3 DLG4
cell adhesion molecule binding X X X X X X X X X X X
receptor activity X X X X X X X X X X X X
neurexin family protein binding X X X X X
neuroligin family protein binding X X X X X X X
calcium channel regulator activity X X X X
acetylcholine receptor binding X X
GKAP/Homer scaffold activity X X X






X X X X
somatostatin receptor binding X
beta-1 adrenergic receptor binding X
D1 dopamine receptor binding X
P2Y1 nucleotide receptor binding X
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data to identify candidate risk alleles associated with com-
plex multigenic diseases [88, 89]. Continued annotation of
neurological processes, as well as other ASD-relevant pro-
cesses such as chromatin re-modeling, developmental pro-
cesses, calcium homeostasis and mitochondrial function,
and the application of pathway-based analysis statistical
approaches may, therefore, help with the identification of
additional ASD risk alleles within genome-wide associ-
ation studies and next generation sequencing projects.Conclusion
The annotation data and ontology terms within the GO
database have been improved through this focused anno-
tation project. Published experimental and patient data
was used to capture the involvement of the NRXN,
NLGN, SHANK and DLG4 proteins in synaptogenesis,
neurogenesis and the behavioral traits seen in ASD. In
order to create descriptive annotations the representation
of synaptogenesis in GO was expanded, with the addition
of 14 expressive terms within the synapse organization do-
main (Table 1, Fig. 4, 5). These new GO terms describe
the more specific aspects of the synapse complex assem-
bly, such as ‘N-methyl-D-aspartate receptor clustering’,
‘neurexin clustering involved in presynaptic membrane as-
sembly’ and ‘presynaptic membrane assembly’, and enable a
detailed description of the biological role of the NRXN,
NLGN, DLG4 and SHANK proteins in synaptogenesis
(see Additional files 5 and 8). Further work on the ontol-
ogy is still needed to improve the description of synaptic
processes using GO terms. Moreover, additional annota-
tion projects would enable the comprehensive annotation
of all ASD-relevant proteins, as well as, full annotation of
neurological processes such as synaptic plasticity, synaptic
organization and synaptic transmission.
GO is a dynamic database that is always expanding as
new annotations are added and new GO terms are cre-
ated in the ontology. The advantage of a focused annota-
tion approach is that it ensures the immediate use of
newly created GO terms for annotations (see Additional
file 9). In contrast, GO terms created during the annotation
of unrelated proteins may end up applied to only a few pro-
teins, for a considerable time. The main challenge in anno-
tating autism-relevant proteins was finding detailed
experimental evidence for each protein. For example,
despite extensive literature review, human NRXN1-β,
NRXN2-α, NRXN2-β, NRXN3-α, and NRXN3-β have no
experimental evidence code supported GO molecular func-
tion terms annotations. Furthermore, there are limited
terms available in the behavioral domain of GO, and the
Neurobehavior Ontology [90] may be better suited to pro-
vide a more comprehensive interpretation of complex be-
havioral traits than can be achieved with GO.Variants in the NRXN, NLGN and SHANK gene fam-
ilies, and in the DLG4 gene, have the potential to result
in impaired synaptic formation and impaired regulation
of synaptic transmission; however, not all of these pro-
teins have been associated with ASD [19]. The quality of
gene annotations incorporated into statistical analysis
tools has a direct impact on the effective interpretation
of many genomic and proteomic datasets. Unfortunately,
not all functional analysis tools include current annota-
tion data; some tools use annotation datasets that are
over a year old. Additional ontology development and
the continued comprehensive annotation of the proteins
involved in ASD-relevant processes, capturing more data
as it emerges in the literature, would ensure the max-
imum utility of the GO data for interpretation of ASD-
focused transcriptomic, proteomic, genome-wide associ-
ation studies and next generation sequencing.
Additional files
Additional file 1: References used to support the annotation of
NLGN, NRXN, SHANK and PSD-95 proteins with GO terms, as part of
the ASD focused annotation project.
Additional file 2: Table S1. List of NRXN, NLGN, SHANK and DLG4
proteins annotated with GO terms, relevant to ASD. Includes hyperlinks to the
QuickGO browser listing current annotations associated with these proteins.
Additional file 3: Table S2. Summary of the number of GO
annotations associated with the NRXN, NLGN, SHANK and DLG4 human,
mouse and rat protein families. The summary tab lists the number of GO
annotations associated with the NRXN, NLGN, SHANK and DLG4 human,
mouse and rat protein families. The all_data tab includes all annotations
associated with these proteins. Downloaded using the QuickGO browser,
filtering on the 47 protein IDs (see Additional file 2), 28 March 2014.
Pre-focus annotations are those generated before the start of this
autism-focused annotation project; Focus annotations are those
generated by this autism-focused annotation project; Other annotations are
those generated by other databases not involved in this autism-focused
annotation project (e.g. MGI, RGD, UniProt); Automatic annotations are
those generated by a variety of automatic scripts based on orthology
(Ensembl), protein domain structure (InterPro) or UniProt Keyword
mapping files (UniProt).
Additional file 4: Table S3. Cellular component GO annotations
associated with the NRXN, NLGN, SHANK and DLG4 human, mouse and
rat protein families. Downloaded using the QuickGO browser, filtering on
the 47 protein IDs (see Additional file 2) and the GO ID GO:0005575, 28
March 2014. An additional column is provided entitled Pre-focus/Focus/
Other/Automatic: Pre-focus annotations are those generated before the
start of this autism-focused annotation project; Focus annotations are
those generated by this autism-focused annotation project; Other
annotations are those generated by other databases after the start of this
autism-focused annotation project (e.g. MGI, RGD, UniProt); Automatic
annotations are those generated by a variety of automatic scripts based
on orthology (Ensembl), protein domain structure (InterPro) or UniProt
Keyword mapping files (UniProt).
Additional file 5: Table S4. Biological process GO annotations
associated with the NRXN, NLGN, SHANK and DLG4 human, mouse and
rat protein families. The ‘direct’ GO term annotations are the GO terms
that have been associated with the protein record. These direct GO terms
have been grouped into broader biological process ‘grouping’ parent GO
terms, or categories. Due to the structure of the ontology there are some
direct GO terms that are child terms of more than one of these broader
GO grouping parent terms. In these instances the annotation is then
represented more than once in the dataset. Downloaded using the
Patel et al. BMC Bioinformatics  (2015) 16:186 Page 15 of 17QuickGO browser, filtering on the 47 protein IDs (see Additional file 2) and
the GO ID GO:0008150, 28 March 2014. An additional column is provided
entitled Pre-focus/Focus/Other/Automatic: Pre-focus annotations are those
generated before the start of this autism-focused annotation project; Focus
annotations are those generated by this autism-focused annotation project;
Other annotations are those generated by other databases after the start of
this autism-focused annotation project (e.g. MGI, RGD, UniProt); Automatic
annotations are those generated by a variety of automatic scripts based on
orthology (Ensembl), protein domain structure (InterPro) or UniProt Keyword
mapping files (UniProt).
Additional file 6: Table S5. Molecular function GO annotations
associated with the NRXN, NLGN, SHANK and DLG4 human, mouse and
rat protein families. Downloaded using the QuickGO browser, filtering on
the 47 protein IDs (see Additional file 2) and the GO ID GO:0003674, 28
March 2014. An additional column is provided entitled Pre-focus/Focus/
Other/Automatic: Pre-focus annotations are those generated before the
start of this autism-focused annotation project; Focus annotations are
those generated by this autism-focused annotation project; Other
annotations are those generated by other databases after the start of this
autism-focused annotation project (e.g. MGI, RGD, UniProt); Automatic
annotations are those generated by a variety of automatic scripts based
on orthology (Ensembl), protein domain structure (InterPro) or UniProt
Keyword mapping files (UniProt).
Additional file 7: Table S6. QuickGO statistics for the source of GO
annotations associated with the NRXN, NLGN, SHANK and DLG4 human,
mouse and rat protein families. Downloaded using the QuickGO browser,
filtering on the 47 protein IDs (see Additional file 2), 28 March 2014.
Additional file 8: Table S7. Summary table of the biological process GO
annotations associated with human DLG4 and the human NRXN, NLGN
and SHANK protein families. All annotations to the human protein
records are included. The ‘direct’ GO term annotations are the GO terms
that have been associated with the protein record (white rows). These
direct GO terms have been grouped into broader biological process
‘grouping’ parent GO terms, or categories (green rows). Due to the
structure of the ontology there are some direct GO terms that are child
terms of more than one of these broader GO grouping parent terms. In
these instances the annotation is then represented more than once in
the dataset. Downloaded using the QuickGO browser, filtering on the 17
human protein IDs (see Additional file 2) and the GO ID GO:0008150, 28
March 2014.
Additional file 9: Table S8. Number of annotations associated with
new GO terms created to support detailed ASD-relevant annotations.
Downloaded using the QuickGO browser, filtering on the new GO IDs
(Table 1), 11 July 2014. Focus annotations are those generated by this
autism-focused annotation project; Other annotations are those
generated by other databases not involved in this autism-focused
annotation project (e.g. MGI, RGD, UniProt); Automatic annotations are
those generated by a variety of automatic scripts based on orthology
(Ensembl), protein domain structure (InterPro) or UniProt Keyword
mapping files (UniProt). For cases when multiple protein IDs are mapped to
a single gene, the manual annotations are counted as a single annotation
not multiple annotations, e.g. MGI has associated Lrcc4 with postsynaptic
density protein 95 clustering [91], based on evidence presented in Kim S
et al., 2006, this annotation is mapped to 4 protein IDs (E9PUX8, Q149E6,
Q8BJ09, Q99PH1) in QuickGO; this is counted as a single annotation.Abbreviations
ASD: Autistic spectrum disorder; BLAST: Basic Local Alignment Search Tool;
GO: Gene Ontology; HCOP: HUGO Gene Nomenclature Committee ortholog
prediction tool; IC: Inferred by Curator; IDA: Inferred from Direct Assay;
IEA: Inferred from Electronic Annotation; IGI: Inferred from Genetic
Interaction; IMP: Inferred from Mutant Phenotype; ISS: Inferred from
Sequence Similarity; MGI: Mouse Genome Informatics; NRXN: Neurexin;
NLGN: Neuroligin; RGD: Rat Genome Database; SNP: Single Nucleotide
Polymorphism.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
SP collected and manually annotated primary articles of genes (NRXN, NLGN
and SHANK gene families, and the DLG4 gene) associated with autism, with
additional annotations by RCL. SP and RCL analyzed the annotation data to
develop the figures and tables. PR created new GO terms in discussion with
SP. SP and RCL drafted the manuscript. All authors revised and approved the
final manuscript.Acknowledgements
R.C.L received support as a British Heart Foundation (BHF) chair scholar and
through funding by BHF grants (RG/13/5/30112 and SP/07/007/23671), a
Parkinson’s UK grant (G-1307), and is supported by the National Institute for
Health Research University College London Hospitals Biomedical Research
Centre. P.R. is funded by the National Human Genome Research Institute
(NHGRI) P41 grant 5P41HG002273-09 to the Gene Ontology Consortium. We
are indebted to Tony Sawford and Dr Maria Martin for the development of
the online EBI GO annotation tool, which was an essential component of this
annotation project. Many thanks to Dr. Jane Lomax, Dr. David Osumi-Sutherland
and other members of the Gene Ontology Editorial Office for useful discussions
about the placement and definition of new GO terms, and to Dr Paul Denny
and Dr Jo Knight for their critical reading of the manuscript. We are also grateful
to all of the curators at UniProt-GOA, the Jackson Laboratory and the Rat
Genome Database, and to Dr. Varsha Khodiyar, for their contributions to the
annotation of these autism-relevant proteins.
Author details
1Institute of Medical Science, University of Toronto, Medical Sciences
Building, 1 King’s College Circle, Toronto M5S 1A8, Canada. 2Campbell Family
Mental Health Research Institute, Centre for Addiction and Mental Health,
250 College Street, Toronto M5T 1R8, Canada. 3Centre for Cardiovascular
Genetics, Institute of Cardiovascular Science, University College London,
Rayne Building, 5 University Street, London WC1E 6JF, UK. 4European
Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI),
Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK. 5The
Gene Ontology Consortium http://geneontology.org/.
Received: 8 May 2014 Accepted: 20 May 2015
References
1. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene
Ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25.
2. Balakrishnan R, Harris MA, Huntley R, Van Auken K, Cherry JM. A guide to
best practices for Gene Ontology (GO) manual annotation. Database
(Oxford). 2013;2013:bat054. doi:10.1093/database/bat054.
3. Pavlidis P, Qin J, Arango V, Mann JJ, Sibille E. Using the gene ontology for
microarray data mining: a comparison of methods and application to age
effects in human prefrontal cortex. Neurochem Res. 2004;29(6):1213–22.
4. Holmans P, Green EK, Pahwa JS, Ferreira MA, Purcell SM, Sklar P, et al. Gene
ontology analysis of GWA study data sets provides insights into the biology
of bipolar disorder. Am J Hum Genet. 2009;85(1):13–24.
doi:10.1016/j.ajhg.2009.05.011.
5. Kendler KS, Kalsi G, Holmans PA, Sanders AR, Aggen SH, Dick DM, et al.
Genomewide association analysis of symptoms of alcohol dependence in
the molecular genetics of schizophrenia (MGS2) control sample. Alcohol
Clin Exp Res. 2011;35(5):963–75. doi:10.1111/j.1530-0277.2010.01427.x.
6. Shi M, Jin J, Wang Y, Beyer RP, Kitsou E, Albin RL, et al. Mortalin: a protein
associated with progression of Parkinson disease? J Neuropathol Exp
Neurol. 2008;67(2):117–24. doi:10.1097/nen.0b013e318163354a.
7. Alam-Faruque Y, Huntley RP, Khodiyar VK, Camon EB, Dimmer EC, Sawford
T, et al. The impact of focused Gene Ontology curation of specific
mammalian systems. PLoS One. 2011;6(12):e27541. doi:10.1371/
journal.pone.0027541.
8. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, et al.
Autism as a strongly genetic disorder: evidence from a British twin study.
Psychol Med. 1995;25(1):63–77.
9. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics.
2004;113(5):e472–86.
10. Kanner L. Autistic disturbances of affective contact. Acta Paedopsychiatrica.
1968;35(4):100.
Patel et al. BMC Bioinformatics  (2015) 16:186 Page 16 of 1711. American Psychiatric Association. Diagnostic and statistical manual of mental
disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.
12. Volkmar FR, McPartland JC. From Kanner to DSM-5: autism as an evolving
diagnostic concept. Annu Rev Clin Psychol. 2014;10:193–212. doi:10.1146/
annurev-clinpsy-032813-153710.
13. Frith U. Autism: A very short introduction. USA: Oxford University Press; 2008.
14. DiCicco-Bloom E, Lord C, Zwaigenbaum L, Courchesne E, Dager SR, Schmitz C,
et al. The developmental neurobiology of autism spectrum disorder.
J Neuroscience. 2006;26(26):6897.
15. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, et al. Strong
association of de novo copy number mutations with autism. Science.
2007;316(5823):445.
16. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. Curr
Opin Genet Dev. 2012;22(3):229–37. doi:10.1016/j.gde.2012.03.002.
17. Abrahams BS, Geschwind DH. Advances in autism genetics: on the
threshold of a new neurobiology. Nat Rev Genet. 2008;9(5):341–55.
18. Persico AM, Napolioni V. Autism genetics. Behav Brain Res. 2013;251:95–112.
doi:10.1016/j.bbr.2013.06.012.
19. Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol.
2007;17(4):434–47. doi:10.1111/j.1750-3639.2007.00102.x.
20. Nguyen T, Sudhof TC. Binding properties of neuroligin 1 and neurexin
1beta reveal function as heterophilic cell adhesion molecules. J Biol Chem.
1997;272(41):26032–9.
21. Scheiffele P, Fan J, Choih J, Fetter R, Serafini T. Neuroligin expressed in
nonneuronal cells triggers presynaptic development in contacting axons.
Cell. 2000;101(6):657–69.
22. Waites CL, Craig AM, Garner CC. Mechanisms of vertebrate synaptogenesis.
Annu Rev Neurosci. 2005;28:251–74.
23. Peca J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN, et al.
Shank3 mutant mice display autistic-like behaviours and striatal dysfunction.
Nature. 2011;472(7344):437–42. doi:10.1038/nature09965.
24. Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, et al.
Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4
are associated with autism. Nat Genet. 2003;34(1):27–9. doi:10.1038/ng1136.
25. Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, Liu XQ, et al.
Mapping autism risk loci using genetic linkage and chromosomal
rearrangements. Nat Genet. 2007;39(3):319–28. doi:10.1038/ng1985.
26. Feng J, Schroer R, Yan J, Song W, Yang C, Bockholt A, et al. High frequency
of neurexin 1beta signal peptide structural variants in patients with autism.
Neurosci Lett. 2006;409(1):10–3. doi:10.1016/j.neulet.2006.08.017.
27. Varoqueaux F, Aramuni G, Rawson RL, Mohrmann R, Missler M, Gottmann K,
et al. Neuroligins determine synapse maturation and function. Neuron.
2006;51(6):741–54. doi:10.1016/j.neuron.2006.09.003.
28. Zhang C, Milunsky JM, Newton S, Ko J, Zhao G, Maher TA, et al. A
neuroligin-4 missense mutation associated with autism impairs neuroligin-4
folding and endoplasmic reticulum export. J Neurosci. 2009;29(35):10843–54.
doi:10.1523/JNEUROSCI.1248-09.2009.
29. Sudhof TC. Neuroligins and neurexins link synaptic function to cognitive
disease. Nature. 2008;455(7215):903–11. doi:10.1038/nature07456.
30. Ylisaukko-oja T, Rehnström K, Auranen M, Vanhala R, Alen R, Kempas E, et al.
Analysis of four neuroligin genes as candidates for autism. Eur J Hum
Genet. 2005;13(12):1285–92.
31. Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP,
et al. X-linked mental retardation and autism are associated with a mutation
in the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet.
2004;74(3):552–7.
32. Yan J, Feng J, Schroer R, Li W, Skinner C, Schwartz CE, et al. Analysis of the
neuroligin 4Y gene in patients with autism. Psychiatr Genet. 2008;18(4):204–7.
doi:10.1097/YPG.0b013e3282fb7fe6.
33. Ushkaryov YA, Hata Y, Ichtchenko K, Moomaw C, Afendis S, Slaughter CA,
et al. Conserved domain structure of beta-neurexins. Unusual cleaved signal
sequences in receptor-like neuronal cell-surface proteins. J Biol Chem.
1994;269(16):11987–92.
34. Bellen HJ, Lu Y, Beckstead R, Bhat MA. Neurexin IV, caspr and paranodin–
novel members of the neurexin family: encounters of axons and glia.
Trends Neurosci. 1998;21(10):444–9.
35. Dean C, Scholl FG, Choih J, DeMaria S, Berger J, Isacoff E, et al. Neurexin
mediates the assembly of presynaptic terminals. Nat Neurosci.
2003;6(7):708–16. doi:10.1038/nn1074.
36. Poliak S, Gollan L, Martinez R, Custer A, Einheber S, Salzer JL, et al. Caspr2, a
new member of the neurexin superfamily, is localized at the juxtaparanodesof myelinated axons and associates with K+ channels. Neuron.
1999;24(4):1037–47.
37. Garcia-Fresco GP, Sousa AD, Pillai AM, Moy SS, Crawley JN, Tessarollo L, et al.
Disruption of axo-glial junctions causes cytoskeletal disorganization and
degeneration of Purkinje neuron axons. Proc Natl Acad Sci U S A.
2006;103(13):5137–42. doi:10.1073/pnas.0601082103.
38. Zahir FR, Baross A, Delaney AD, Eydoux P, Fernandes ND, Pugh T, et al. A
patient with vertebral, cognitive and behavioural abnormalities and a de
novo deletion of NRXN1alpha. J Med Genet. 2008;45(4):239–43.
doi:10.1136/jmg.2007.054437.
39. Gauthier J, Siddiqui TJ, Huashan P, Yokomaku D, Hamdan FF, Champagne N,
et al. Truncating mutations in NRXN2 and NRXN1 in autism spectrum
disorders and schizophrenia. Hum Genet. 2011;130(4):563–73.
doi:10.1007/s00439-011-0975-z.
40. Vaags AK, Lionel AC, Sato D, Goodenberger M, Stein QP, Curran S, et al. Rare
deletions at the neurexin 3 locus in autism spectrum disorder. Am J Hum
Genet. 2012;90(1):133–41. doi:10.1016/j.ajhg.2011.11.025.
41. Alarcon M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV, Bomar JM, et al.
Linkage, association, and gene-expression analyses identify CNTNAP2 as an
autism-susceptibility gene. Am J Hum Genet. 2008;82(1):150–9.
doi:10.1016/j.ajhg.2007.09.005.
42. Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, et al. Mutations in
the SHANK2 synaptic scaffolding gene in autism spectrum disorder and
mental retardation. Nat Genet. 2010;42(6):489–91. doi:10.1038/ng.589.
43. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F,
et al. Mutations in the gene encoding the synaptic scaffolding protein
SHANK3 are associated with autism spectrum disorders. Nat Genet.
2007;39(1):25–7. doi:10.1038/ng1933.
44. Sato D, Lionel AC, Leblond CS, Prasad A, Pinto D, Walker S, et al. SHANK1
Deletions in Males with Autism Spectrum Disorder. Am J Hum Genet.
2012;90(5):879–87. doi:10.1016/j.ajhg.2012.03.017.
45. Craig AM, Kang Y. Neurexin-neuroligin signaling in synapse development.
Curr Opin Neurobiol. 2007;17(1):43–52. doi:10.1016/j.conb.2007.01.011.
46. Eyre TA, Wright MW, Lush MJ, Bruford EA. HCOP: a searchable database
of human orthology predictions. Brief Bioinform. 2007;8(1):2–5.
doi:10.1093/bib/bbl030.
47. Day-Richter J, Harris MA, Haendel M, Lewis S. OBO-Edit–an ontology editor for
biologists. Bioinformatics. 2007;23(16):2198–200. doi:10.1093/bioinformatics/
btm112.
48. Graf ER, Zhang X, Jin SX, Linhoff MW, Craig AM. Neurexins induce
differentiation of GABA and glutamate postsynaptic specializations via
neuroligins. Cell. 2004;119(7):1013–26. doi:10.1016/j.cell.2004.11.035.
49. Ko J, Zhang C, Arac D, Boucard AA, Brunger AT, Sudhof TC. Neuroligin-1
performs neurexin-dependent and neurexin-independent functions in
synapse validation. EMBO J. 2009;28(20):3244–55. doi:10.1038/
emboj.2009.249.
50. Levinson JN, Li R, Kang R, Moukhles H, El-Husseini A, Bamji SX. Postsynaptic
scaffolding molecules modulate the localization of neuroligins. Neuroscience.
2010;165(3):782–93. doi:10.1016/j.neuroscience.2009.11.016.
51. Chubykin AA, Atasoy D, Etherton MR, Brose N, Kavalali ET, Gibson JR, et al.
Activity-dependent validation of excitatory versus inhibitory synapses by
neuroligin-1 versus neuroligin-2. Neuron. 2007;54(6):919–31.
doi:10.1016/j.neuron.2007.05.029.
52. Hung AY, Futai K, Sala C, Valtschanoff JG, Ryu J, Woodworth MA, et al.
Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial
learning in mice lacking Shank1. J Neurosci. 2008;28(7):1697–708.
doi:10.1523/JNEUROSCI.3032-07.2008.
53. Uemura T, Mori H, Mishina M. Direct interaction of GluRdelta2 with Shank
scaffold proteins in cerebellar Purkinje cells. Mol Cell Neurosci.
2004;26(2):330–41. doi:10.1016/j.mcn.2004.02.007.
54. Cho KO, Hunt CA, Kennedy MB. The rat brain postsynaptic density fraction
contains a homolog of the Drosophila discs-large tumor suppressor protein.
Neuron. 1992;9(5):929–42.
55. Sun XY, Takagishi Y, Okabe E, Chishima Y, Kanou Y, Murase S, et al. A novel
Caspr mutation causes the shambling mouse phenotype by disrupting
axoglial interactions of myelinated nerves. J Neuropathol Exp Neurol.
2009;68(11):1207–18. doi:10.1097/NEN.0b013e3181be2e96.
56. Chubykin AA, Liu X, Comoletti D, Tsigelny I, Taylor P, Sudhof TC. Dissection
of synapse induction by neuroligins: effect of a neuroligin mutation
associated with autism. J Biol Chem. 2005;280(23):22365–74. doi:10.1074/
jbc.M410723200.
Patel et al. BMC Bioinformatics  (2015) 16:186 Page 17 of 1757. Uemura T, Lee SJ, Yasumura M, Takeuchi T, Yoshida T, Ra M, et al. Trans-synaptic
interaction of GluRdelta2 and Neurexin through Cbln1 mediates synapse
formation in the cerebellum. Cell. 2010;141(6):1068–79. doi:10.1016/
j.cell.2010.04.035.
58. Etherton MR, Tabuchi K, Sharma M, Ko J, Sudhof TC. An autism-associated
point mutation in the neuroligin cytoplasmic tail selectively impairs AMPA
receptor-mediated synaptic transmission in hippocampus. EMBO J.
2011;30(14):2908–19. doi:10.1038/emboj.2011.182.
59. Barrow SL, Constable JR, Clark E, El-Sabeawy F, McAllister AK, Washbourne P.
Neuroligin1: a cell adhesion molecule that recruits PSD-95 and NMDA
receptors by distinct mechanisms during synaptogenesis. Neural Dev.
2009;4:17. doi:10.1186/1749-8104-4-17.
60. Wittenmayer N, Korber C, Liu H, Kremer T, Varoqueaux F, Chapman ER, et al.
Postsynaptic Neuroligin1 regulates presynaptic maturation. Proc Natl Acad
Sci U S A. 2009;106(32):13564–9. doi:10.1073/pnas.0905819106.
61. Bakkaloglu B, O’Roak BJ, Louvi A, Gupta AR, Abelson JF, Morgan TM, et al.
Molecular cytogenetic analysis and resequencing of contactin associated
protein-like 2 in autism spectrum disorders. Am J Hum Genet.
2008;82(1):165–73. doi:10.1016/j.ajhg.2007.09.017.
62. Oiso S, Takeda Y, Futagawa T, Miura T, Kuchiiwa S, Nishida K, et al.
Contactin-associated protein (Caspr) 2 interacts with carboxypeptidase E in the
CNS. J Neurochem. 2009;109(1):158–67. doi:10.1111/j.1471-4159.2009.05928.x.
63. Poliak S, Salomon D, Elhanany H, Sabanay H, Kiernan B, Pevny L, et al.
Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons
depends on Caspr2 and TAG-1. J Cell Biol. 2003;162(6):1149–60.
doi:10.1083/jcb.200305018.
64. Wang X, McCoy PA, Rodriguiz RM, Pan Y, Je HS, Roberts AC, et al. Synaptic
dysfunction and abnormal behaviors in mice lacking major isoforms of
Shank3. Hum Mol Genet. 2011;20(15):3093–108. doi:10.1093/hmg/ddr212.
65. Chen X, Nelson CD, Li X, Winters CA, Azzam R, Sousa AA, et al. PSD-95 is
required to sustain the molecular organization of the postsynaptic density.
J Neurosci. 2011;31(17):6329–38. doi:10.1523/JNEUROSCI.5968-10.2011.
66. Mondin M, Labrousse V, Hosy E, Heine M, Tessier B, Levet F, et al. Neurexin-
neuroligin adhesions capture surface-diffusing AMPA receptors through PSD-95
scaffolds. J Neurosci. 2011;31(38):13500–15. doi:10.1523/JNEUROSCI.6439-10.2011.
67. Verpelli C, Dvoretskova E, Vicidomini C, Rossi F, Chiappalone M, Schoen M,
et al. Importance of Shank3 protein in regulating metabotropic glutamate
receptor 5 (mGluR5) expression and signaling at synapses. J Biol Chem.
2011;286(40):34839–50. doi:10.1074/jbc.M111.258384.
68. Hines RM, Wu L, Hines DJ, Steenland H, Mansour S, Dahlhaus R, et al.
Synaptic imbalance, stereotypies, and impaired social interactions in mice
with altered neuroligin 2 expression. J Neurosci. 2008;28(24):6055–67.
doi:10.1523/JNEUROSCI.0032-08.2008.
69. Gutierrez RC, Hung J, Zhang Y, Kertesz AC, Espina FJ, Colicos MA. Altered
synchrony and connectivity in neuronal networks expressing an autism-
related mutation of neuroligin 3. Neuroscience. 2009;162(1):208–21.
doi:10.1016/j.neuroscience.2009.04.062.
70. Bang ML, Owczarek S. A matter of balance: role of neurexin and neuroligin at the
synapse. Neurochem Res. 2013;38(6):1174–89. doi:10.1007/s11064-013-1029-9.
71. Comoletti D, De Jaco A, Jennings LL, Flynn RE, Gaietta G, Tsigelny I, et al.
The Arg451Cys-neuroligin-3 mutation associated with autism reveals a
defect in protein processing. J Neurosci. 2004;24(20):4889–93.
doi:10.1523/JNEUROSCI.0468-04.2004.
72. Zweier C, de Jong EK, Zweier M, Orrico A, Ousager LB, Collins AL, et al.
CNTNAP2 and NRXN1 are mutated in autosomal-recessive Pitt-Hopkins-like
mental retardation and determine the level of a common synaptic protein
in Drosophila. Am J Hum Genet. 2009;85(5):655–66.
doi:10.1016/j.ajhg.2009.10.004.
73. Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, Takahashi N,
et al. Haploinsufficiency of the autism-associated Shank3 gene leads to
deficits in synaptic function, social interaction, and social communication.
Mol Autism. 2010;1(1):15. doi:10.1186/2040-2392-1-15.
74. Jamain S, Radyushkin K, Hammerschmidt K, Granon S, Boretius S,
Varoqueaux F, et al. Reduced social interaction and ultrasonic
communication in a mouse model of monogenic heritable autism. Proc
Natl Acad Sci U S A. 2008;105(5):1710–5. doi:10.1073/pnas.0711555105.
75. Feyder M, Karlsson RM, Mathur P, Lyman M, Bock R, Momenan R, et al.
Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene
variation with phenotypes relevant to autism spectrum disorders and
Williams’ syndrome. Am J Psychiatry. 2010;167(12):1508–17.
doi:10.1176/appi.ajp.2010.10040484.76. Wohr M, Roullet FI, Hung AY, Sheng M, Crawley JN. Communication
impairments in mice lacking Shank1: reduced levels of ultrasonic
vocalizations and scent marking behavior. PLoS One. 2011;6(6):e20631.
doi:10.1371/journal.pone.0020631.
77. Etherton MR, Blaiss CA, Powell CM, Sudhof TC. Mouse neurexin-1alpha
deletion causes correlated electrophysiological and behavioral changes
consistent with cognitive impairments. Proc Natl Acad Sci U S A.
2009;106(42):17998–8003. doi:10.1073/pnas.0910297106.
78. Blundell J, Tabuchi K, Bolliger MF, Blaiss CA, Brose N, Liu X, et al. Increased
anxiety-like behavior in mice lacking the inhibitory synapse cell adhesion
molecule neuroligin 2. Genes Brain Behav. 2009;8(1):114–26.
doi:10.1111/j.1601-183X.2008.00455.x.
79. Bolliger MF, Frei K, Winterhalter KH, Gloor SM. Identification of a novel
neuroligin in humans which binds to PSD-95 and has a widespread
expression. Biochem J. 2001;356(Pt 2):581–8.
80. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, et al. Coupling of
mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic
density proteins. Neuron. 1999;23(3):583–92.
81. Uchino S, Wada H, Honda S, Nakamura Y, Ondo Y, Uchiyama T, et al. Direct
interaction of post-synaptic density-95/Dlg/ZO-1 domain-containing synaptic
molecule Shank3 with GluR1 alpha-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid receptor. J Neurochem. 2006;97(4):1203–14.
doi:10.1111/j.1471-4159.2006.03831.x.
82. Xu J, Paquet M, Lau AG, Wood JD, Ross CA, Hall RA. beta 1-adrenergic
receptor association with the synaptic scaffolding protein membrane-
associated guanylate kinase inverted-2 (MAGI-2). Differential regulation of
receptor internalization by MAGI-2 and PSD-95. J Biol Chem.
2001;276(44):41310–7. doi:10.1074/jbc.M107480200.
83. Siow NL, Choi RC, Xie HQ, Kong LW, Chu GK, Chan GK, et al. ATP induces
synaptic gene expressions in cortical neurons: transduction and
transcription control via P2Y1 receptors. Mol Pharmacol. 2010;78(6):1059–71.
doi:10.1124/mol.110.066506.
84. Alam-Faruque Y, Hill DP, Dimmer EC, Harris MA, Foulger RE, Tweedie S, et al.
Representing kidney development using the gene ontology. PLoS One.
2014;9(6):e99864. doi:10.1371/journal.pone.0099864.
85. Mutowo-Meullenet P, Huntley RP, Dimmer EC, Alam-Faruque Y, Sawford T,
Jesus Martin M, O’Donovan C, Apweiler R. Use of Gene Ontology
Annotation to understand the peroxisome proteome in humans. Database
(Oxford). 2013;2013:bas062. doi:10.1093/database/bas062.
86. The Gene Ontology’s Reference Genome Project: a unified framework for
functional annotation across species. PLoS Comput Biol. 2009;5(7):e1000431.
doi:10.1371/journal.pcbi.1000431.
87. Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res.
2014;42(Database issue):D191-8. doi:10.1093/nar/gkt1140.
88. Holmans P, Moskvina V, Jones L, Sharma M, Vedernikov A, Buchel F, et al. A
pathway-based analysis provides additional support for an immune-related
genetic susceptibility to Parkinson’s disease. Hum Mol Genet.
2013;22(5):1039–49. doi:10.1093/hmg/dds492.
89. Duncan LE, Holmans PA, Lee PH, O’Dushlaine CT, Kirby AW, Smoller JW,
et al. Pathway analyses implicate glial cells in schizophrenia. PLoS One.
2014;9(2):e89441. doi:10.1371/journal.pone.0089441.
90. Gkoutos GV, Schofield PN, Hoehndorf R. The neurobehavior ontology: an
ontology for annotation and integration of behavior and behavioral phenotypes.
Int Rev Neurobiol. 2012;103:69–87. doi:10.1016/B978-0-12-388408-4.00004-6.
91. Kim S, Burette A, Chung HS, Kwon SK, Woo J, Lee HW, et al. NGL family
PSD-95-interacting adhesion molecules regulate excitatory synapse
formation. Nat Neurosci. 2006;9(10):1294–301. doi:10.1038/nn1763.
